Objective: To investigate whether preadmission 25-hydroxyvitamin D (25(OH)D) levels are associated with the risk of hospital-acquired Clostridium difficile infection (HACDI). Materials and Methods: Our retrospective cohort study focused on 568 adult patients from 2 Boston teaching hospitals between August 1993 and November 2006. All patients had 25(OH)D levels measured before hospitalization and were at risk for HACDI (defined as the presence of C difficile toxin A or B in stool samples obtained >48 hours after hospitalization). We performed multivariable regression analyses to test the association of prehospital 25(OH)D levels with HACDI while adjusting for clinically relevant covariates. Results: In these 568 patients, mean (SD) 25(OH)D level was 19 (12) ng/mL, and 11% of patients met criteria for incident HACDI. Following adjustment for age, sex, race (nonwhite vs white), patient type (medical vs surgical), and Deyo-Charlson index, patients with 25(OH)D levels <10 ng/mL had higher odds of HACDI (odds ratio [OR], 2.90; 95% confidence interval [CI], 1.01–8.34) compared with patients with 25(OH)D levels ≥30 ng/mL. When patients with HACDI were analyzed relative to a larger patient cohort without HACDI (n = 5047), those with 25(OH)D levels <10 ng/mL (OR, 4.96; 95% CI, 1.84–13.38) and 10–19.9 ng/mL (OR, 3.36; 95% CI, 1.28–8.85) had higher adjusted odds of HACDI compared with patients with 25(OH)D levels ≥30 ng/mL. Conclusions: In our cohort of adult patients, vitamin D status before hospital admission was inversely associated with the risk of developing HACDI. These data support the need for randomized, controlled trials to test the role of vitamin D supplementation to prevent HACDI.
DubberkeERReskeKAOlsenMAMcDonaldLCFraserVJ. Short- and long-term attributable costs of Clostridium difficile–associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497-504.
4.
KyneLHamelMBPolavaramRKellyCP. Health care costs and mortality associated with nosocomial diarrhea due toClostridium difficile. Clin Infect Dis. 2002;34(3):346-353.
5.
O’BrienJALahueBJCaroJJDavidsonDM. The emerging infectious challenge of Clostridium difficile–associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28(11):1219-1227.
6.
CohenSHGerdingDNJohnsonS. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
7.
ButlerMBlissDDrekonjaD. Effectiveness of early diagnosis, prevention, and treatment of Clostridium difficile infection. Rockville, MD: Agency for Healthcare Research and Quality (US). 2011. [Epub ahead of print].
8.
BartlettJG. Narrative review: the new epidemic of Clostridium difficile–associated enteric disease. Ann Intern Med. 2006;145(10):758-764.
9.
SunenshineRHMcDonaldLC. Clostridium difficile–associated disease: new challenges from an established pathogen. Cleve Clin J Med. 2006;73(2):187-197.
10.
KellyCP. A 76-year-old man with recurrent Clostridium difficile–associated diarrhea: review of C. difficile infection. JAMA. 2009;301(9):954-962.
11.
SehulsterLChinnRY. Guidelines for environmental infection control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-10):1-42.
12.
AdamsJSHewisonM. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4(2):80-90.
13.
YoussefDARanasingheTGrantWBPeirisAN. Vitamin D’s potential to reduce the risk of hospital-acquired infections. Dermatoendocrinology. 2012;4(2):167-175.
14.
YoussefDGrantWBPeirisAN. Vitamin D deficiency: a potential risk factor for Clostridium difficile infection. Risk Manag Healthc Policy. 2012;5:115-116.
15.
KuriacoseROliveKE. Prevalence of vitamin D deficiency and insufficiency in northeast Tennessee. South Med J. 2008;101(9):906-909.
16.
PellicaneAJWysockiNMSchnitzerTJ. Prevalence of 25-hydroxyvitamin D deficiency in the outpatient rehabilitation population. Am J Phys Med Rehabil. 2010;89(11):899-904.
17.
FishEBeversteinGOlsonDReinhardtSGarrenMGouldJ. Vitamin D status of morbidly obese bariatric surgery patients. J Surg Res. 2010;164(2):198-202.
18.
BogunovicLKimADBeamerBSNguyenJLaneJM. Hypovitaminosis D in patients scheduled to undergo orthopaedic surgery: a single-center analysis. J Bone Joint Surg Am. 2010;92(13):2300-2304.
19.
GindeAALiuMCCamargoCAJr.Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169(6):626-632.
20.
BraunAChangDMahadevappaK. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med. 2011;39(4):671-677.
21.
HivertMFGrantRWShraderPMeigsJB. Identifying primary care patients at risk for future diabetes and cardiovascular disease using electronic health records. BMC Health Serv Res. 2009;9:170.
22.
HugBLLipsitzSRSegerDLKarsonASWrightSCBatesDW. Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease. Swiss Med Wkly. 2009;139(51-52):737-746.
23.
LinderJABatesDWWilliamsDHConnollyMAMiddletonB. Acute infections in primary care: accuracy of electronic diagnoses and electronic antibiotic prescribing. J Am Med Inform Assoc. 2006;13(1):61-66.
24.
ZagerSMenduMLChangD. Neighborhood poverty rate and mortality in patients receiving critical care in the academic medical center setting. Chest. 2011;139(6):1368-1379.
25.
HolickMFBinkleyNCBischoff-FerrariHA. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
26.
QuanHSundararajanVHalfonP. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
27.
QuanHLiBCourisCM. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682.
28.
CharlsonMEPompeiPAlesKLMacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
29.
RapoportJGehlbachSLemeshowSTeresD. Resource utilization among intensive care patients: managed care vs traditional insurance. Arch Intern Med. 1992;152(11):2207-2212.
30.
CowperDCKubalJDMaynardCHynesDM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12(7):462-468.
31.
SohnMWArnoldNMaynardCHynesDM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
32.
SchistermanEFWhitcombBW. Use of the Social Security Administration Death Master File for ascertainment of mortality status. Popul Health Metr. 2004;2(1):2.
33.
NewmanTBBrownAN. Use of commercial record linkage software and vital statistics to identify patient deaths. J Am Med Inform Assoc. 1997;4(3):233-237.
34.
HollisBWKamerudJQSelvaagSRLorenzJDNapoliJL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem. 1993;39(3):529-533.
35.
LangeNLitonjuaAGibbonsFGiovannucciEChristopherK. Pre-hospital vitamin D concentration, mortality and bloodstream infection in a hospitalized patient population. Am J Med. 2013;126(7):640.e19-27.
36.
SchistermanEFColeSRPlattRW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488-495.
37.
ClevelandW. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74(368):829-836.
38.
ClevelandWDevlinS. Locally-weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83(403):596-610.
39.
YoussefDBaileyBEl AbbassiA. Healthcare costs of Staphylococcus aureus and Clostridium difficile infections in veterans: role of vitamin D deficiency. Epidemiol Infect. 2010;138(9):1322-1327.
40.
PinheirodaSilvaFMachadoMC. Antimicrobial peptides: clinical relevance and therapeutic implications. Peptides. 2012;36(2):308-314.
41.
DurrUHSudheendraUSRamamoorthyA. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408-1425.
42.
TollinMBergmanPSvenbergTJornvallHGudmundssonGHAgerberthB. Antimicrobial peptides in the first line defence of human colon mucosa. Peptides. 2003;24(4):523-530.
43.
VoraPYoudimAThomasLS. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol. 2004;173(9):5398-5405.
44.
QuraishiSALitonjuaAAMoromizatoT. Association between prehospital vitamin D status and hospital-acquired bloodstream infections. Am J Clin Nutr. 2013;98(4):952-959.
45.
MoromizatoTLitonjuaAABraunABGibbonsFKGiovannucciEChristopherKB. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill [published online August 26, 2013]. Crit Care Med.
46.
PepinJSahebNCoulombeMA. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254-1260.
47.
ConcatoJShahNHorwitzRI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-1892.
48.
PlatzEALeitzmannMFHollisBWWillettWCGiovannucciE. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004;15(3):255-265.
49.
QuraishiSACamargoCAJr.Vitamin D in acute stress and critical illness. Curr Opin Clin Nutr Metab Care. 2012;15(6):625-634.
50.
PepinJValiquetteLAlaryME. Clostridium difficile–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466-472.
51.
EsperAMMossMLewisCANisbetRManninoDMMartinGS. The role of infection and comorbidity: factors that influence disparities in sepsis. Crit Care Med. 2006;34(10):2576-2582.
52.
JengLYamshchikovAVJuddSE. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28.
53.
KuijperEJCoignardBTullP. Emergence of Clostridium difficile–associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(suppl 6):2-18.
54.
KellyCPLaMontJT. Clostridium difficile—more difficult than ever. N Engl J Med. 2008;359(18):1932-1940.
55.
EmersonCBEyzaguirreLMAlbrechtJSComerACHarrisADFurunoJP. Healthcare-associated infection and hospital readmission. Infect Control Hosp Epidemiol. 2012;33(6):539-544.
56.
WiegandPNNathwaniDWilcoxMHStephensJShelbayaAHaiderS. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81(1):1-14.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
